My whiteboard has fourteen ingredient names on it, and only one word is circled twice: cost. That's the gap in most brain health writing aimed at people past fifty — everyone talks about cognitive function like it's priceless, and almost nobody runs the actual numbers on what a gain in memory or focus costs per month. I treat supplement tracking the way I used to treat a capital purchase request at the firm: what went in, and what came back out. Senior wellness marketing skips that math entirely. I don't.
Two monitors sit on the desk I hauled home when my old firm downsized. The left screen stays open to the master tracking file. The right one is for research — receipts, vendor pages, whatever marketing claim I'm trying to verify that week. Under the window, the supplement bottles on the shelf are lined up in the order I started testing them, not by brand and not by price. My wife says the whole setup has more structure than our actual tax returns ever did, which is probably a fair assessment.
Every bottle and every audio track on that shelf gets judged the same way I used to judge a client's capital expenditure — through Return on Investment. ROI asks one plain question: what did this cost, and what measurable return did it produce? Applied to a brain supplement, the return isn't revenue. It shows up as a smaller number in my "Word Recall Lag" column, or a higher one in "Subjective Focus." Run enough products through that filter and two categories land on opposite ends of the ledger — traditional capsule supplements priced at the top of the category, and newer audio-based programs priced well below them.
Before I trusted my own columns enough to compare anything, I ran fish oil capsules from Costco every single morning for six months and watched both of those columns sit flat the entire time. No movement in recall, no movement in focus, just a recurring charge and a bottle that needed replacing. That's the baseline I measure everything else against now.
The Ledger Behind Brain Health Supplement Tracking
NeuroPrime and Neuro-Thrive both sit at the premium end of the capsule category — traditional pill format, familiar delivery method, the kind of packaging that looks like it belongs in a pharmacy aisle instead of a vitamin shop. That familiarity is worth something to a lot of buyers, and I don't fault the instinct. But the market-validation numbers tell a different story than the packaging does. NeuroPrime's Gravity score sits around 43, and its conversion rate is the lowest of anything I track, close to two-tenths of one percent. Neuro-Thrive isn't much stronger — Gravity in the low twenties, conversion under two-tenths of a percent as well. In accounting terms, that's a high-ticket asset with a soft demand curve. People buy it because it looks credible, not because a large pool of buyers has already proven the return.
Premium Capsules: The High-Ticket Column
That's not a cost-benefit ratio I'd sign off on if a client brought it to me for approval. High price, low market traction, a format that appeals mostly to people who already trust capsules on principle. Nothing wrong with that preference on its own. The problem is when someone assumes the higher sticker price must be buying a proportionally higher result — that's the same faulty logic I used to see in expense reports, where "premium" got confused with "effective" because nobody bothered to check the actual output column.
How Timing Affects Your Return
Most capsule labels are built around a circadian-aligned schedule — take it with breakfast, let it absorb across a normal daytime, done. That instruction assumes whoever swallows it wakes around six or seven and sleeps that same night. For a night-shift nurse or a rotating-schedule warehouse worker, "morning" might be four in the afternoon. Run the identical ROI math on that population and the return column collapses, not because the ingredients changed, but because the delivery window got mismatched against the body's actual schedule. That's a timing problem, not a product problem, and no label on any bottle mentions it.
I ran that theory past Neil Trevisan, a former colleague from my accounting days who's suspicious of any conclusion I reach before he's poked three holes in it. We were splitting a rotisserie chicken from Central Market on Lovers Lane, and I laid out the timing mismatch for him the way I used to lay out a finding for an audit committee. His first question was whether I had a real control group behind that claim or just a hunch wearing a spreadsheet's clothes. Fair question. Neil has sat across a desk from me long enough to know when I'm reaching for a conclusion the numbers haven't earned yet, and he's usually right to push back.
Weighing the Audio-Based Alternative
On the other side of the ledger sits The Brain Song, an audio-based program that skips capsules, digestion, and any fixed morning window entirely. It carries the strongest market-validation signal in the whole category — a Gravity score comfortably above 200 — and it enters at a fraction of what the premium capsules cost. I broke down the specific numbers behind that comparison in The Brain Song Review: My Data-Backed Verdict on Clear Thinking, so I won't repeat the full spreadsheet here. What matters for this comparison is that a low entry cost paired with a high validation signal is close to the best combination an accountant could ask for in any asset.
The Genius Song sits at a similar price tier and posts the highest conversion rate of anything in the group I track, north of one percent, which in a crowded category is a strong signal of sustained demand rather than a one-time spike. Neither audio program produces the kind of afternoon crash I've noticed with caffeine, a pattern I've tracked in more detail in Caffeine vs. Natural Supplements. No crash means no repayment period on the back end, which is its own kind of return. I keep The Genius Song on hand as the secondary option for days when I want a different angle than The Brain Song offers, particularly for tasks that lean more creative than analytical.
A reader named Dorinda Szymanski, a retired nurse in Wisconsin who found my site through a Reddit thread about homemade cognitive testing and started keeping her own log not long after, emails every so often just to ask whether I've ruled out a placebo baseline before crediting a product with a result. It's a fair check, and one I don't always pass on the first draft. Separating an actual effect from simply expecting one to show up is its own discipline, and I've dedicated a full audit to exactly that question elsewhere. The clearest single data point I have on the recall side is a name that surfaced mid-sentence while I was talking with my son-in-law — a word I'd been chasing for days that just arrived on its own, no searching required. I track that kind of moment the same careful way I track everything else, under a verbal-recall column with its own dedicated method that I've written up separately.
How I structure that whole tracking file — the tabs, the columns, the test-start dates on the shelf — is its own topic and deserves more room than one paragraph here. The gap between what a supplement label promises and what the spreadsheet actually shows also turned out to be wider than I expected going in, wide enough that I gave it a full write-up of its own rather than a passing mention. And the afternoon fog numbers specifically, separate from the morning baseline, get their own dedicated audit rather than a summary here.
Choosing Your Best Column
If you want a familiar delivery format and you're not troubled by a soft return on investment, a premium capsule like NeuroPrime or Neuro-Thrive isn't a reckless choice — you're paying for a format you already trust, and that has real value even when the demand data is thin. But if your schedule doesn't match the standard morning routine printed on every capsule label, or you'd rather test something at a lower cost before committing to a bigger one, the audio-based route clears the ROI bar by a wider margin in every column I track, with The Brain Song as the primary pick and The Genius Song as the backup option for a different kind of task. That's not a verdict on which set of ingredients works better in some clinical sense. It's a verdict on which asset pays you back faster for what you put into it.
Two ledgers, one bottom line: the higher price didn't buy the better outcome in either column I keep, and the cheaper, less conventional format is the one carrying the stronger validation numbers right now. Reasonable people can still choose the capsule for reasons that have nothing to do with ROI — comfort with the format chief among them. My spreadsheet doesn't have an opinion on comfort. It just has an opinion on the numbers, and the numbers currently favor the audio column.
None of this replaces a conversation with an actual doctor, especially if what you're noticing feels less like ordinary aging and more like a real change in how your memory or focus is holding up day to day. I'm a retired accountant with a well-organized spreadsheet, not a clinician, and the two are not interchangeable no matter how many tabs I add.